Fibrocell Science Inc

Fibrocell Science — Investor Presentation (May 2013)

36 slides from Fibrocell Science's investor presentation, May 7, 2013

  1. Slide 1: Fibrocell

    f) FIBROCELL & May 7, 2013 SS

  2. Slide 2: Forward Looking Statement

    2 This presentation includes statements that are "forward-looking statements." Forward-looking statements include, without limitation, our ability (i) to timely commence our clinical programs in 2013 to treat patients with restrictive burn scars and vocal cord scars, and a timely completion of these

  3. Slide 3: Investor Highlights

    Investor Highlights Autologous cell therapy company on cutting edge of developing first-in-class medical applications using fibroblasts LAVIV(r) - lead product Indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults One of only three FDA-approved cell bas

  4. Slide 4: Status

    Status Aesthetic (Nasolabial Lines and Other) FDA-approved for smile line wrinkles in June 2011 Restrictive Burn Scars Phase II study initiated Efficacy data expected mid-2014 Vocal Cord Scarring Positive pilot study published in Laryngoscope; abstract online: http://www.ncbi.nlm.nih.gov/pubmed/2128

  5. Slide 5: Unlocking the Potential of the Autologous Fibroblast

    Aesthetics Autologous Fibroblast Cell Therapy for Unmet Medical Indications (Scarring) Autologous Fibroblast Cell Therapies for Rare and Ultra Rare Diseases 5 Unlocking the Potential of the Autologous Fibroblast

  6. Slide 6: Significant Addressable Markets

    6 American Society for Aesthetic Plastic Surgery. www.ameriburn.org; Goodis. J and E.d. Schraga. Burns, thermal. eMedicine Journal Personal communication with several expert burn clinicians Cohen, (2010); Dailey et al. (2007); Roy et al. (2005); Poels et al. (2003); Koufman and Isaacson (1991); Pain

  7. Slide 7: The Autologous Fibroblast

    The Autologous Fibroblast

  8. Slide 8: Fibroblast Cells

    Most common cells of connective tissue in animals Produce collagen and other extracellular matrix proteins, which form the infrastructure of human tissue Produce an array of growth factors and other cytokines that aid in cell signaling and wound repair Fibroblast Cells 8

  9. Slide 9: Fibroblasts: Location in Skin

    Fibroblasts: Location in Skin 9

  10. Slide 10: Dermal Fibroblasts

    Dermal fibroblasts produce: Collagen type I Collagen type III Collagen type VII Elastin Hyaluronic acid (hyaluronin) Matrix metalloproteinases (MMPs) (1) Artist's interpretation Dermal Fibroblasts Matrix metalloproteinases refers to a group of proteins that play an important role in tissue remodelin

  11. Slide 11: Aesthetics

    Aesthetics

  12. Slide 12: LAVIV

    12 Positioned as premium aesthetic First in New Class - Personalized Aesthetics Replaces a person's own fibroblast cells LAVIV has received recognition in national beauty and fashion magazines Allure magazine 'Breakthrough Award' Wall Street Journal Technology Innovation Awards Edison Awards Silver

  13. Slide 13: Restrictive Burn Scarring

    Restrictive Burn Scarring 13

  14. Slide 14: Restrictive Burn Scarring: Overview

    Currently no FDA-approved drugs Azficel-T treatment: potential improvement in range of motion, reduction in pain and aesthetic improvement Potential indication for unmet medical need: 45,000 yearly hospitalizations for severe burns (1) (excluding military and existing victims) Promising results in o

  15. Slide 15: Burn Patient Case Studies

    Burn Patient Case Studies * *Note: Photos from LAVIV prescribers. Not from clinical studies. These are not restrictive burn scar patients. Case 1 Case 2 15

  16. Slide 16: Functional Benefit Demonstrated in Burn Patients

    16 Burn Scars Before 5 Weeks Post Injury 7 Months Post Injury 18 Months Post Injury Area Treated with Azficel-T Note: Photos from LAVIV prescribers. Not from clinical studies. Functional Benefit Demonstrated in Burn Patients

  17. Slide 17: Restrictive Burn Scarring: Status

    Phase II Trial: Single site, double-blind, randomized, placebo- controlled, 21 subjects Subjects: Unilateral restrictive burn scars of a jointed area 20-50 percent restriction in normal range of motion; no improvement after physical therapy Measurement Scales: Range of Motion Measurement Brief Pain

  18. Slide 18: Vocal Cord Scarring

    Vocal Cord Scarring

  19. Slide 19: Vocal Cord Scarring: Overview

    No currently approved drugs Most commonly encountered finding is loss of voice Results from surgery, radiation therapy, vocal cord trauma and idiopathic causes Positive pilot study results published in peer-reviewed journal The Laryngoscope, 2011. (1) Azficel-T well-tolerated when injected into voca

  20. Slide 20: Vocal Cord Scarring: Status

    Phase II protocol submitted to FDA Estimated initiation of trial 2H 2013 Efficacy data expected in 2H 2014 Proposed Endpoints: Impression of improvement in voice quality (VAS) Change from baseline in the noise-to-harmonic ratio (dB) Absolute and percentage change from baseline in the Voice Handicap

  21. Slide 21: Acne Scarring

    Acne Scarring

  22. Slide 22: Acne Scarring: Overview

    22 No currently approved drugs Permanent discoloration and/or indentation of the skin as a result of moderate to severe acne Opportunity to capture large market share No current medical treatment Completed one Phase II study: Results published in peer-reviewed journal Dermatologic Surgery, available

  23. Slide 23: Acne Scarring: Phase II Study Results

    23 Efficacy: - Fibroblast treatment demonstrated statistically significant number of responders in subject and evaluator assessments at four months - 98% of patients who completed the study indicated interest in receiving additional treatment Safety: - Most common adverse events: erythema (11.1%), s

  24. Slide 24: Acne Scarring: Follow-Up Photos from Study

    24 Acne Scarring: Follow-Up Photos from Study 25 Month Photos Anecdotally Demonstrate Potential Long-Lasting Effect Time Photos provided by Gilly S. Munavalli, MD, MHS, FACMS, Dermatology, Laser & Vein Specialists of the Carolinas, Charlotte, NC

  25. Slide 25: Intrexon Collaboration: Genetically Modified Fibroblasts for Rare and Ultra Rare Diseases

    Intrexon Collaboration: Genetically Modified Fibroblasts for Rare and Ultra Rare Diseases

  26. Slide 26: Intrexon Collaboration

    Proposed new therapeutic product: Genetically modified (GM) fibroblast Up-regulated to produce Collagen VII Employ Intrexon's synthetic biology platforms for optimal gene expression from GM fibroblasts Pre-clinical activity underway in GM fibroblasts for rare and ultra rare diseases i.e. recessive d

  27. Slide 27: RDEB: Overview

    Initial target: recessive dystrophic epidermolysis bullosa (RDEB) Epidermolysis bullosa: genetic conditions that cause blistering and fragile skin Mutations in the COL7A1 gene cause disease This gene helps create type VII collagen Type VII collagen key in strengthening and stabilizing the skin It is

  28. Slide 28: UCLA Collaboration: Stem Cell Program

    UCLA Collaboration: Stem Cell Program

  29. Slide 29: Stem Cell Collaboration

    Identified a rare mesenchymal stem cell (MSC) population from adult human skin The data was published in the article, "Vega-Crespo et al 2013, BioResearch Open Access, 1:25" (http://online.liebertpub.com/doi/pdf/10.1089/biores.2012.0204) Goal to purify MSCs using biomarkers to identify a number of p

  30. Slide 30: The Only Créme of Its Kind

    = The Only Créme of Its Kind B

  31. Slide 31: Autologous Creme

    Personalized autologous cream Conditioned complete growth media from the azficel-T production process is collected, concentrated and used to formulate a personalized topical cosmetic 19 subject cosmetic clinical study to be completed in May 2013 Autologous Creme(tm) 31

  32. Slide 32: Financials

    Financials

  33. Slide 33: Financial Information

    Strong cash position; US $31.3 million on hand at end of December 2012 Large private capital raise completed in October 2012, investor syndicate led by Third Security, an investment firm led by RJ Kirk No debt on the balance sheet Company's capital structure greatly simplified All outstanding prefer

  34. Slide 34: Capitalization Table

    Common shares (post reverse split) 26.2M Warrants 6.3M Options .6M Fully diluted shares outstanding 33.1M Fibrocell has been cleared to submit NYSE MKT listing application Capitalization Table 34

  35. Slide 35: Summary

    Summary

  36. Slide 36: Investor Highlights

    Autologous cell therapy company on cutting edge of developing first in class medical applications Strategic focus on a robust pipeline for LAVIV medical applications: Restrictive burn scarring, vocal cord scarring and acne scarring LAVIV(r) - lead product Indicated for improvement of the appearance

Fibrocell Science — Investor Presentation (May 2013) on 6ix